Starpharma Holdings Limited (SPL.AX)
AUD 0.1
(3.09%)
AUD 0.1
(3.09%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -8.16 Million AUD | 47.79% |
| 2023 | -15.63 Million AUD | 3.19% |
| 2022 | -16.15 Million AUD | 18.13% |
| 2021 | -19.73 Million AUD | -34.43% |
| 2020 | -14.67 Million AUD | -2.97% |
| 2019 | -14.25 Million AUD | -38.59% |
| 2018 | -10.28 Million AUD | 32.41% |
| 2017 | -15.21 Million AUD | 28.53% |
| 2016 | -21.29 Million AUD | -12.36% |
| 2015 | -18.95 Million AUD | -29.48% |
| 2014 | -14.63 Million AUD | -179.88% |
| 2013 | -5.22 Million AUD | 61.71% |
| 2012 | -13.65 Million AUD | -52.95% |
| 2011 | -8.93 Million AUD | -40.01% |
| 2010 | -6.37 Million AUD | -54.54% |
| 2009 | -4.12 Million AUD | 44.91% |
| 2008 | -7.49 Million AUD | -3.4% |
| 2007 | -7.24 Million AUD | 3.69% |
| 2006 | -7.52 Million AUD | 0.83% |
| 2005 | -7.58 Million AUD | -37.98% |
| 2004 | -5.49 Million AUD | -3040.52% |
| 2003 | -175.06 Thousand AUD | -429.32% |
| 2002 | 53.15 Thousand AUD | 101.36% |
| 2001 | -3.9 Million AUD | -120.43% |
| 2000 | -1.77 Million AUD | -51.56% |
| 1999 | -1.16 Million AUD | 8.0% |
| 1998 | -1.27 Million AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1.03 Million AUD | 0.0% |
| 2024 Q4 | -7.13 Million AUD | 0.0% |
| 2024 FY | -8.16 Million AUD | 47.79% |
| 2023 Q2 | -8.27 Million AUD | 0.0% |
| 2023 FY | -15.63 Million AUD | 3.19% |
| 2023 Q4 | -7.36 Million AUD | 0.0% |
| 2022 FY | -16.15 Million AUD | 18.13% |
| 2022 Q4 | -7.7 Million AUD | 0.0% |
| 2022 Q2 | -8.44 Million AUD | 0.0% |
| 2021 Q2 | -10.43 Million AUD | 0.0% |
| 2021 Q4 | -9.3 Million AUD | 0.0% |
| 2021 FY | -19.73 Million AUD | -34.43% |
| 2020 Q4 | -8.81 Million AUD | 0.0% |
| 2020 Q2 | -5.86 Million AUD | 0.0% |
| 2020 FY | -14.67 Million AUD | -2.97% |
| 2019 FY | -14.25 Million AUD | -38.59% |
| 2019 Q2 | -7.26 Million AUD | 0.0% |
| 2019 Q4 | -6.98 Million AUD | 0.0% |
| 2018 Q4 | -4.05 Million AUD | 0.0% |
| 2018 FY | -10.28 Million AUD | 32.41% |
| 2018 Q2 | -6.23 Million AUD | 0.0% |
| 2017 Q2 | -8.33 Million AUD | 0.0% |
| 2017 FY | -15.21 Million AUD | 28.53% |
| 2016 FY | -21.29 Million AUD | -12.36% |
| 2016 Q2 | -10.03 Million AUD | 0.0% |
| 2015 Q4 | -10.41 Million AUD | 0.0% |
| 2015 Q2 | -8.53 Million AUD | 0.0% |
| 2015 FY | -18.95 Million AUD | -29.48% |
| 2014 FY | -14.63 Million AUD | -179.88% |
| 2014 Q4 | -9.06 Million AUD | 0.0% |
| 2014 Q2 | -5.57 Million AUD | 0.0% |
| 2013 Q2 | -1.83 Million AUD | 46.35% |
| 2013 Q1 | -3.41 Million AUD | 0.0% |
| 2013 Q3 | -1.3 Million AUD | 28.64% |
| 2013 Q4 | -3.39 Million AUD | -159.86% |
| 2013 FY | -5.22 Million AUD | 61.71% |
| 2012 Q1 | -2.23 Million AUD | 0.0% |
| 2012 FY | -13.65 Million AUD | -52.95% |
| 2012 Q4 | -3.41 Million AUD | 0.0% |
| 2012 Q3 | -3.41 Million AUD | 0.0% |
| 2012 Q2 | -3.41 Million AUD | -52.95% |
| 2011 FY | -8.93 Million AUD | -40.01% |
| 2011 Q3 | -2.23 Million AUD | 0.0% |
| 2011 Q1 | -1.59 Million AUD | 0.0% |
| 2011 Q4 | -2.23 Million AUD | 0.0% |
| 2011 Q2 | -2.23 Million AUD | -40.01% |
| 2010 Q3 | -1.59 Million AUD | 0.0% |
| 2010 FY | -6.37 Million AUD | -54.54% |
| 2010 Q2 | -1.59 Million AUD | -54.54% |
| 2010 Q1 | -1.03 Million AUD | 0.0% |
| 2010 Q4 | -1.59 Million AUD | 0.0% |
| 2009 Q2 | -1.03 Million AUD | 44.91% |
| 2009 Q3 | -1.03 Million AUD | 0.0% |
| 2009 Q4 | -1.03 Million AUD | 0.0% |
| 2009 Q1 | -1.87 Million AUD | 0.0% |
| 2009 FY | -4.12 Million AUD | 44.91% |
| 2008 Q2 | -1.87 Million AUD | -3.4% |
| 2008 Q3 | -1.87 Million AUD | 0.0% |
| 2008 FY | -7.49 Million AUD | -3.4% |
| 2008 Q4 | -1.87 Million AUD | 0.0% |
| 2008 Q1 | -1.81 Million AUD | 0.0% |
| 2007 FY | -7.24 Million AUD | 3.69% |
| 2007 Q4 | -1.81 Million AUD | 0.0% |
| 2007 Q1 | -1.88 Million AUD | 0.0% |
| 2007 Q3 | -1.81 Million AUD | 0.0% |
| 2007 Q2 | -1.81 Million AUD | 3.69% |
| 2006 Q1 | -1.89 Million AUD | 0.0% |
| 2006 Q4 | -1.88 Million AUD | 0.0% |
| 2006 Q3 | -1.88 Million AUD | 0.0% |
| 2006 FY | -7.52 Million AUD | 0.83% |
| 2006 Q2 | -1.88 Million AUD | 0.83% |
| 2005 FY | -7.58 Million AUD | -37.98% |
| 2005 Q3 | -1.89 Million AUD | 0.0% |
| 2005 Q4 | -1.89 Million AUD | 0.0% |
| 2005 Q2 | -1.89 Million AUD | 0.0% |
| 2005 Q1 | - AUD | 0.0% |
| 2004 Q4 | - AUD | 0.0% |
| 2004 Q1 | -43.76 Thousand AUD | 0.0% |
| 2004 Q2 | - AUD | 100.0% |
| 2004 Q3 | - AUD | 0.0% |
| 2004 FY | -5.49 Million AUD | -3040.52% |
| 2003 Q2 | -43.76 Thousand AUD | -429.34% |
| 2003 Q4 | -43.76 Thousand AUD | 0.0% |
| 2003 Q3 | -43.76 Thousand AUD | 0.0% |
| 2003 Q1 | 13.28 Thousand AUD | 0.0% |
| 2003 FY | -175.06 Thousand AUD | -429.32% |
| 2002 Q4 | 13.28 Thousand AUD | 0.0% |
| 2002 Q3 | 13.28 Thousand AUD | 0.0% |
| 2002 Q1 | -976.6 Thousand AUD | 0.0% |
| 2002 Q2 | 13.28 Thousand AUD | 101.36% |
| 2002 FY | 53.15 Thousand AUD | 101.36% |
| 2001 Q1 | -443 Thousand AUD | 0.0% |
| 2001 Q2 | -976.6 Thousand AUD | -120.45% |
| 2001 Q4 | -976.6 Thousand AUD | 0.0% |
| 2001 Q3 | -976.6 Thousand AUD | 0.0% |
| 2001 FY | -3.9 Million AUD | -120.43% |
| 2000 Q2 | -443 Thousand AUD | -51.56% |
| 2000 FY | -1.77 Million AUD | -51.56% |
| 2000 Q4 | -443 Thousand AUD | 0.0% |
| 2000 Q3 | -443 Thousand AUD | 0.0% |
| 2000 Q1 | -292.29 Thousand AUD | 0.0% |
| 1999 FY | -1.16 Million AUD | 8.0% |
| 1999 Q1 | -317.69 Thousand AUD | 0.0% |
| 1999 Q2 | -292.29 Thousand AUD | 8.0% |
| 1999 Q3 | -292.29 Thousand AUD | 0.0% |
| 1999 Q4 | -292.29 Thousand AUD | 0.0% |
| 1998 Q4 | -317.69 Thousand AUD | 0.0% |
| 1998 Q2 | -317.69 Thousand AUD | 0.0% |
| 1998 Q3 | -317.69 Thousand AUD | 0.0% |
| 1998 FY | -1.27 Million AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 6.96 Million AUD | 217.238% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -462.621% |
| Zelira Therapeutics Limited | -36.56 Million AUD | 77.672% |
| Biome Australia Limited | -1.67 Million AUD | -388.863% |
| Patrys Limited | -3.53 Million AUD | -130.705% |
| Orthocell Limited | -7.18 Million AUD | -13.703% |
| Imugene Limited | -149.68 Million AUD | 94.545% |
| Noxopharm Limited | -3.57 Million AUD | -128.193% |
| PYC Therapeutics Limited | -37.72 Million AUD | 78.357% |
| Chimeric Therapeutics Limited | -12.52 Million AUD | 34.836% |
| Prescient Therapeutics Limited | -8.23 Million AUD | 0.887% |
| Proteomics International Laboratories Limited | -6.37 Million AUD | -28.054% |
| Cynata Therapeutics Limited | -9.74 Million AUD | 16.211% |
| CSL Limited | 2.64 Billion AUD | 100.309% |
| Arovella Therapeutics Limited | -8.74 Million AUD | 6.643% |
| Bio-Gene Technology Limited | -2.4 Million AUD | -238.912% |
| Clinuvel Pharmaceuticals Limited | 35.63 Million AUD | 122.912% |
| Nanollose Limited | -1.15 Million AUD | -605.977% |
| Memphasys Limited | -4.44 Million AUD | -83.813% |
| Invex Therapeutics Ltd | -1.64 Million AUD | -397.317% |
| NeuroScientific Biopharmaceuticals Limited | 324.21 Thousand AUD | 2618.429% |
| Amplia Therapeutics Limited | -4.5 Million AUD | -81.305% |
| Botanix Pharmaceuticals Limited | -13.86 Million AUD | 41.131% |
| Island Pharmaceuticals Limited | -2.86 Million AUD | -185.059% |
| Race Oncology Limited | -13.81 Million AUD | 40.916% |
| Nyrada Inc. | -1.38 Million AUD | -489.009% |
| Telix Pharmaceuticals Limited | 5.21 Million AUD | 256.688% |
| Dimerix Limited | -17.07 Million AUD | 52.182% |
| PharmAust Limited | -9.03 Million AUD | 9.603% |
| Immutep Limited | -39.89 Million AUD | 79.534% |
| Clarity Pharmaceuticals Ltd | -42.32 Million AUD | 80.709% |
| Alterity Therapeutics Limited | -19.12 Million AUD | 57.304% |
| BTC Health Limited | 1.05 Million AUD | 873.723% |
| Acrux Limited | -5.8 Million AUD | -40.776% |
| Neuren Pharmaceuticals Limited | 157.08 Million AUD | 105.198% |
| Biotron Limited | -3.43 Million AUD | -137.595% |
| Tissue Repair Ltd | -4.13 Million AUD | -97.313% |
| AdAlta Limited | -5.38 Million AUD | -51.73% |
| Radiopharm Theranostics Limited | -47.94 Million AUD | 82.972% |
| Hexima Limited | -933.87 Thousand AUD | -774.316% |
| AnteoTech Limited | -8.88 Million AUD | 8.057% |
| Paradigm Biopharmaceuticals Limited | -58.65 Million AUD | 86.079% |
| Recce Pharmaceuticals Ltd | -17.66 Million AUD | 53.77% |
| Avecho Biotechnology Limited | -3.43 Million AUD | -137.592% |
| Actinogen Medical Limited | -13.04 Million AUD | 37.406% |
| Immuron Limited | -6.93 Million AUD | -17.703% |
| Argenica Therapeutics Limited | -5.47 Million AUD | -49.01% |